Figure 1.
Effect of methylophiopogonanone A (MO-A) on A, food efficiency ratio B, visceral fat, C, abdominal adipose tissue, and D, fecal lipids in hyperlipidemic rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with normal control (NC) group; **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 2.
Effect of methylophiopogonanone A (MO-A) on A, daily food intake, B, final body weight, C, body weight, and D, liver index in hyperlipidemic rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with normal control (NC) group; **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 3.
Effect of methylophiopogonanone A (MO-A) on serum levels of A, total cholesterol (TC), B, triacylglycerol (TG), C, high-density lipoprotein cholesterol (HDL-C), and D, low-density lipoprotein cholesterol (LDL-C) in hyperlipidemia rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with normal control (NC) group; *P<0.05, **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 4.
Effect of methylophiopogonanone A (MO-A) on hepatic lipid levels of A, triacylglycerol (TG) and B, total cholesterol (TC) in hyperlipidemia rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with NC group; **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 5.
Effect of methylophiopogonanone A (MO-A) on hepatic A, lipoprotein lipase (LPL) and C, hepatic lipase (HL) activities and serum B, LPL and D, HL activities in hyperlipidemia rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with normal control (NC) group; *P<0.05, **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 6.
Effect of methylophiopogonanone A (MO-A) on A and B, aspartate transaminase (AST) and C and D, alanine aminotransferase (ALT) levels in hyperlipidemia rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with NC group; **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 7.
Effect of methylophiopogonanone A (MO-A) on hepatic mRNA expression of A, CoA carboxylase (ACC), B, sterol regulatory element-binding protein 1c (SREBP-1C), C, low-density lipoprotein receptor (LDLR), and D, peroxisome proliferator-activated receptor α (PPARα) in hyperlipidemia rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with normal control (NC) group; *P<0.05, **P<0.01, compared with high-fat diet (HFD) group (ANOVA).
Figure 8.
Expression of proteins in the livers of hyperlipidemia rats. A, Western blotting images of peroxisome proliferator-activated receptor α (PPARα), low-density lipoprotein receptor (LDLR), sterol regulatory element-binding protein 1c (SREBP-1C), and CoA carboxylase (ACC) protein expression. Relative expression of B, PPARα protein, C, LDLR protein, D, SREBP-1C protein, and E, ACC protein. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with normal control (NC) group; *P<0.05, **P<0.01, compared with high-fat diet (HFD) group (ANOVA). MO-A: methylophiopogonanone A.
Figure 9.
Effect of methylophiopogonanone A (MO-A) on A, protein expression of carnitine palmitoyltransferase-1 (CPT-1), B, activity of CPT-1, and C, activity of fatty acid oxidase (FAO) in hyperlipidemia rats. Data are reported as means±SD, n=8 rats in each group. #P<0.05, compared with NC group; **P<0.01, compared with high-fat diet (HFD) group (ANOVA).